Welcome to Radiotherapy Network

Our mission is to provide best possible radiation oncology care for our patients. We believe that the residents who live in Southwest Metropolitan area of Chicago should be able to get access to all the state of the art treatment options for their cancer care at home without traveling far. We have worked hard to develop radiation treatment programs to provide tertiary care with clinical research and most complete offering of treatment options.

We are one of the few centers in the area to provide specialized treatment options such as body and cranial stereotactic radiosurgery, Radioimmunotherapy and radiopharmaceutical treatment. We also provide full range of standard radiotherapy treatment options such as IMRT, 3-D conformal treatment planning, High Dose Rate Brachytherapy, Low Dose Rate Brachytherapy.

Our ultimate goal in building such a comprehensive program is to provide the best chance for cure with least risk to our patients. All of our radiation oncologists are American Board of Radiology board-certifed physicians. We work with multidisplinary treatment teams who are all very well trained and qualified to provide best care.

Services available

• Cyberknife Cranial and Body Stereotactic Radiosurgery

  The CyberKnife® Robotic Radiosurgery System is the world’s first and only radiosurgery system designed to treat tumors anywhere in the body with sub-millimeter accuracy. Using image guidance technology and computer controlled robotics, the CyberKnife System is designed to continuously track the tumor, detect its location and correct for tumor and patient movement in real-time throughout the treatment. Because of its extreme precision, the CyberKnife System does not require invasive head or body frames to stabilize patient movement, vastly increasing the system’s flexibility.

  Unlike traditional radiosurgery systems that can only treat tumors in the head and neck, the CyberKnife System can treat both intracranial and extracranial tumors. In fact, extracranial treatments currently represent more than 50 percent of CyberKnife System procedures in the United States, including those of the spine, lung, prostate, liver and pancreas. The CyberKnife System provides an additional option to many patients diagnosed with previously inoperable or surgically complex tumors, or patients who may be looking for an alternative to surgery.

• Intensity Modulated Radiation Therapy

  Intensity modulated radiation therapy (IMRT) is a specialized form of 3D-CRT that allows radiation to be more exactly shaped to fit your tumor. With IMRT, the radiation beam can be broken up into many "beamlets," and the intensity of each beamlet can be adjusted individually. Using IMRT, it may be possible to further limit the exact amount of radiation that is received by normal tissues that are near the tumor. In some situations, this may also allow a higher dose of radiation to be delivered to the tumor, increasing the chance of a cure.

  For our patients, this means less side effects and higher chance of cure and local control. We are happy to be one of the few centers in the chicago area to offer this technology to benefit our patients

• Radioactive Isotope Monoclonal Antiboty Therapy

  Bexxar (tositumomab and iodine I 131 ) and Zevalin (Ibritumomab and Indium 111 or Yttrium 90) are radiolabled monoclonal antibodies for the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma (NHL), with and without transformation, whose disease is resistant to Rituximab and has relapsed following chemotherapy.

  These are antibodies with radioactive isotopes attached. The drug attaches to a protein found only on the surface of B lymphocytes such as cancerous B-cells found in many forms of Non-Hodgkin's lymphoma. The radioactivity targets the B-cell, destroying it. This is a targeted therapy that attacks the antigen on the cell surface of the tumor cells, delivering cytotoxic radiation directly to the cancerous cells.

• Click here for more treatment options available in our centers

• Clinical Trials

Breast Cancer CALGB 40101
CALGB 40101: Cyclophosphamide and Doxorubicin (4 vs 6 cycles) vs Paclitaxel (12 Weeks vs 18 Weeks) as adjuvant therapy for women with node-negative breast cancer:  A 2X2 Factorial phase III randomized study.

Breast Cancer CALGB 79809
CALGB 79809: Phase III trial of intravenous zoledronic acid(Zometa) in the preventio of bone loss in localized breast cancer patients with chemotherapy-induced ovarian failure.

Breast Ca, NCIC CTG MA 27
A randomized phase III trial of Exemestane vs Anastrozole with or without Celecoxib in postmenopausal women with receptor positive primary breast cancer

Small Cell Lung Cancer, S0124
Randomized phase III trial of Cisplatin and Irinotecan vs Cisplatin and Etoposide in patients with extensive stage small cell lung cancer

Pancreatic Cancer S0205
A phase III randomized open-label study comparing Gemcitabine plus Cetuximab(IMC-C225) versus Gemcitabine as first-line therapy of patients with advanced pancreatic cancer

Breast Cancer NSABP B-35
A clinical trial comparing anastrozole with Tamoxifen in postmenopausal patients with ductal carcinoma in situ(DCIS) undergoing lumpectomy with radiation therapy

Colon Cancer N0147
A randomized phase III trial of Irinotecan and/or Oxaliplatin plus 5-fluorouracil(5-FU)/Leucovorin(CF) after curative resection for patients with stage III colon cancer

Gastric and GE Junction Adeno Ca CALBG 80101
A phase III Trial of adjuvant chemoradiation after resection of gastric and gastroesophageal adenocarcinoma

Gastro-Intestinal Stromal Tumor(GIST) ACOSOG-Z9001
A phase III randomized double-blind study of adjuvant ST1571 (Gleevec Tm) versus placebo in patients following the resection of primary Gastro-Intestinal Stromal Tumor(GIST)

Colon CA, Post-op, NSABP C-08
A Phase III clinical trial comparing infusional 5-Fluorouracil, Leucovorin, and Oxaliplain(mFOLFOX6) every two weeks with Bevacizumab to the same regimen without Bevacizumab for the treatment of patients with resected Stages II and III carcinoma of the colon.